Dtic-dome and Pulmonary embolism - a phase IV clinical study of FDA data

Summary:

Pulmonary embolism is reported as a side effect among people who take Dtic-dome (dacarbazine), especially for people who are male, 50-59 old, also take Dexamethasone, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Pulmonary embolism when taking Dtic-dome. It is created by eHealthMe based on reports of 206 people who have side effects when taking Dtic-dome from the FDA, and is updated regularly.

What is Dtic-dome?

Dtic-dome has active ingredients of dacarbazine. eHealthMe is studying from 206 Dtic-dome users. Check the latest studies of Dtic-dome.

What is Pulmonary embolism?

Pulmonary embolism (blockage of the main artery of the lung) is found to be associated with 2,334 drugs and 2,959 conditions by eHealthMe. Check the latest studies of Pulmonary embolism.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

206 people reported to have side effects when taking Dtic-dome.
Among them, 11 people (5.34%) have Pulmonary embolism.

Could Dtic-dome cause Pulmonary embolism?

Among these 11 people:

What is the gender of people who have Pulmonary embolism when taking Dtic-dome? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Pulmonary embolism when taking Dtic-dome? *

What are other drugs people take besides Dtic-dome? *

What are other side effects people have besides Pulmonary embolism? *

Activated Partial Thromboplastin Time Prolonged: 4 people, 36.36%
Fibrin D Dimer Increased: 4 people, 36.36%
Haemoglobin Decreased: 3 people, 27.27%
Aspartate Aminotransferase Increased: 3 people, 27.27%
Blood Creatinine Increased: 3 people, 27.27%
Blood Urea Increased: 3 people, 27.27%
Disease Recurrence: 3 people, 27.27%
Febrile Neutropenia (fever with reduced white blood cells): 3 people, 27.27%
Haematocrit Decreased: 3 people, 27.27%
White Blood Cell Count Decreased: 3 people, 27.27%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 27.27%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 27.27%
Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Dtic-dome and have Pulmonary embolism?

- Check whether Pulmonary embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dtic-dome:

Dtic-dome (206 reports)

Browse all side effects of Dtic-dome:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary embolism:

Pulmonary embolism (2,334 drugs)

Browse all the conditions that are associated with Pulmonary embolism:

Pulmonary embolism (2,959 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dacarbazine (the active ingredients of Dtic-dome) and Dtic-dome (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.